IPCAA, Ethical MedTech




Code National Transposition Status – Overview

Country	National Association	Status	Comments				
Austria	Austromed	yes	AGM on the 29 March 2017. DS not allowed.				
Baltics	MedTech Baltics	To be determined	New Member. Trasposition is planned durning 2019.				
Belgium	BeMedTech	To be determined	Positive board decision to ban DS in 2016. Most likely implementation by 2020, but AGM decision pending.				
Croatia	Cromed	To be determined	New Member				
Cyprus	SAAIEK	Yes	Approved by AGM in October 2018, Code fully into force as of 1st Januay 2019				
Czech Republic	CzechMed	Yes	Transposition in March 2018				
	CZEDMA	Yes	Approved by AGM in April 2017, effective January 2018				
Denmark	Medicoindustrien	Yes	Approved in 22 March 2018, DS ban in 1 January 2019				
	Dialab	To be determined	The Board is informed about the Code				
Finland	Sai Lab	yes	Approved on 14 December 2017, DS banned as of 1st January 2019				
France	Snitem	To be determined	Discussions ongoing. A best practice workshop took place in December 2018				
	SIDIV	To be determined	Discussions ongoing. A best practice workshop took place in December 2018				
Germany	BVMed	Yes (Code not binding)	Board decision Oct. 2017 - Addendum to Article 8 Continued Medical Education, Section 2, No. 2 b; BVMed Code				
	VDGH	N/A	No plans for formal transposition but proactive promotion of the Code internally and externally				
	Spectaris	Yes (Code not binding)	AGM approved new Code on 28 Sept. 2017; in effect as of 1st January 2018				
Greece	SIEV	yes	Transposition of MTE Code approved on the 22 June 2017, enter into force 1 January 2018				
Hungary	AMDM	yes	Approval for the Code in April 2018. Implementation as of 1st of June 2018				
	HIVDA	yes	Trasposition in 2017, DS banned as of 1st January 2019				
Ireland	Irish Medtech Association	yes	Transposition in 2017, Code in full force as of 2018				
	IMSTA	yes	Transposition in 2017, Code in full force as of 2018				
Italy	Assobiomedica	yes	Transposition in 2018. DS banned as of 1st January 2019. Transparency in 2021				
Middle East	MECOMED	yes	Phase out of direct sponsorship as of January 2018. Transparency in 2019				
Norway	MedTek Norge	N/A	Agreement with stakeholders, no transposition needed. Alignment with MTE Code already the case				
	LabNorge	N/A	Agreement with stakeholders, no transposition needed. Alignment with MTE Code already the case				
Poland	POLMED	yes	Adoption by AGM in 2017; 2018 in force				
	MedTech Polska	yes	Adoption by AGM in 2017; 2018 in force				
Portugal	APORMED	yes	AGM approved, implementation in July 2018				
	APIFARMA	yes	Transposition as of 1.1.2018				
Romania	AFPM	Ongoing	AGM apporoval on 14.02.2018. Transposition with small modifications to be approved during 2018, awating information				
Russia	IMEDA	Ongoing	Analysis of MTE Code ongoing (translation available). DS not allowed by law				
Slovakia	SK-MED	yes	Transposition with small adaptation. 1.2.2018				
	SEDMA	yes	Transposition as of 1.1. 2018				
Slovenia	SLO-MED	yes	Code fully into force as of 1.1.2018				
	SIEDMA	yes	Code fully into force as of 1.1.2018				
Spain	FENIN	yes	Board approval on 20.12.2016, DS banned as of 1.1.2018				
Sweden	Swedish Medtech	N/A	Agreement with stakeholders, no transposition needed. Alignment with MTE Code already the case				
	Swedish Labtech	N/A	Agreement with stakeholders, no transposition needed. Alignment with MTE Code already the case				
Switzerland	Swiss MedTech	yes	New Code went into force in June 2017; direct sponsorship ban in force starting 1 January 2018				
	SVDI	To be determined					
The Netherlands	NEFEMED	To be determined	Code implementation to be re-discussed in 2019				
	FHI	To be determined	Code implementation to be re-discussed in 2019				
	DIAGNED	To be determined	Code implementation to be re-discussed in 2019				
Turkey	Arted	Ongoing	Transposition to be voted in January 2019 AGM, entry into force 1st January 2020				
UK	АВНІ	yes	Transposition already started, new Code in force as of January 2017. Phase out DS 1.1.2019				
	BIVDA	yes	Board decision in December 2016; Code in full force as of January 2018				



CVS in numbers


Total number of submissions - January 2019



	2013	2014	2015	2016	2017	2018	2019
Total submissions	604	867	1184	1499	2242	3572	1601 (Jan '19)
Increase		43%	36%	21%	49%	59%	



Third Party Procedure Training - Form





Third Party Procedure Training - Form

Date	Session Name	Theoretical Session Duration (mins)	Practical Sessi Duration (mins		Hands-on Session Duration (mins)		Hospitality Duration (mins)	
2019 1 JUL MON	Session 1 - Title	30	÷ -	\$	-	‡	-	‡
	Session 2 - Title	-	‡ 40	‡		‡	-	‡
	Session 3 - Tilte	-	- *	‡	50	\$	-	\$

Guidelines for NAs on establishing a CVS system

Recommendations

- National Associations can establish local assessment systems to review national events.
- National Associations should seek legal advice on establishing a national assessment systems (eg: for compliance with competition laws)
- Alignment on the assessed criteria: it is recommended for NAs to maintain similar criteria as CVS Europe to ensure maximum convergence in the way events are assessed.
- National Associations (NAs) need to establish a local Compliance Panel which role will be to oversee the system management, hear appeals on decisions made and hear complaints on Code infringements.
- Enforce strict submission deadlines.
- Have some flexibility by allowing a correction notice period to event organisers for events that present non-compliant aspect.
- Seep history/archive of all documents that were used during the evaluation process.